Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec receives positive CHMP opinion on Avonex Pen

Biogen Idec receives positive CHMP opinion on Avonex Pen

21st April 2011

Biogen Idec has received a positive opinion on the approval of its new Avonex Pen multiple sclerosis (MS) treatment from a European Medicines Agency committee.

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the therapy option be approved for use among patients with relapsing MS and those with a single demyelinating event.

Data from a phase IIIb clinical trial has supported the efficacy of the fully integrated intramuscular autoinjector, which is designed to improve the convenience and injection anxiety associated with Avonex treatment.

The device has also received approval from Canadian healthcare regulators this week.

Dr Douglas Williams, executive vice-president for research and development at Biogen Idec, said: "For many patients and their caregivers, Avonex Pen is a significant advancement, especially for those who desire a more convenient method of administration."

This comes after the firm also received CHMP backing for a label update for the MS drug Tysabri earlier this week.ADNFCR-8000103-ID-800508760-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.